Page last updated: 2024-11-05

troglitazone and Atherosclerosis

troglitazone has been researched along with Atherosclerosis in 3 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Atherosclerosis: A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.

Research Excerpts

ExcerptRelevanceReference
"Insulin sensitization and reduction in blood pressure may be contributory mechanisms by which troglitazone reduced subclinical atherosclerosis progression in this cohort of well-controlled insulin-dependent patients with clinical characteristics suggesting type 2 diabetes."5.12Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes. ( Alaupovic, P; Buchanan, TA; Garcia, K; Hodis, HN; Hollen, B; Li, Y; Mack, WJ; Sevilla, D; Stewart, Y; Torres, M; Zheng, L, 2006)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tsai, JS1
Chuang, LM1
Chen, CS1
Liang, CJ1
Chen, YL1
Chen, CY1
McCarthy, C1
O'Gaora, P1
James, WG1
de Gaetano, M1
McClelland, S1
Fitzgerald, DJ1
Belton, O1
Hodis, HN1
Mack, WJ1
Zheng, L1
Li, Y1
Torres, M1
Sevilla, D1
Stewart, Y1
Hollen, B1
Garcia, K1
Alaupovic, P1
Buchanan, TA1

Trials

1 trial available for troglitazone and Atherosclerosis

ArticleYear
Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes.
    Diabetes care, 2006, Volume: 29, Issue:7

    Topics: Adult; Aged; Atherosclerosis; Carotid Artery, Common; Chromans; Diabetes Mellitus, Type 2; Double-Bl

2006

Other Studies

2 other studies available for troglitazone and Atherosclerosis

ArticleYear
Troglitazone and Δ2Troglitazone enhance adiponectin expression in monocytes/macrophages through the AMP-activated protein kinase pathway.
    Mediators of inflammation, 2014, Volume: 2014

    Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Atherosclerosis; Cell Adhesion; Cell Line; Chro

2014
SorLA modulates atheroprotective properties of CLA by regulating monocyte migration.
    Atherosclerosis, 2010, Volume: 213, Issue:2

    Topics: Animals; Atherosclerosis; Cell Movement; Chemokine CCL2; Chromans; Humans; Linoleic Acids, Conjugate

2010